The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Zdzitovetskaya N.D.

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University

Karachyova Yu.V.

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University

Ruksha T.G.

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University

Simakova N.A.

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University

Current view on the treatment of moderate and severe psoriasis

Authors:

Zdzitovetskaya N.D., Karachyova Yu.V., Ruksha T.G., Simakova N.A.

More about the authors

Read: 4098 times


To cite this article:

Zdzitovetskaya ND, Karachyova YuV, Ruksha TG, Simakova NA. Current view on the treatment of moderate and severe psoriasis. Russian Journal of Clinical Dermatology and Venereology. 2023;22(4):434‑440. (In Russ.)
https://doi.org/10.17116/klinderma202322041434

Recommended articles:
Historical aspe­cts and prospects of psoriasis treatment. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):284-292
Psychodermatological aspe­cts of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):403-411
Clinical discussion of patients with follicular occlusion syndrome and como­rbid pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(5):596-603
Mechanism of action of various therapies for viti­ligo. Pharmacologist’s and dermatovenerologist’s perspective. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(6):734-741
Bronchial asthma in pregnant women. Journal of Respiratory Medi­cine. 2025;(4):63-70

References:

  1. Psoriasis. Clinical guidelines. All-Russian public organization «Russian society of dermatologists and cosmetologists». 2019. (In Russ.).
  2. Levonchuk EA, Yahnitskii GG, Tarasevich SM, et al. Modern ideas about pathogenesis and treatment of psoriasis. Text: electronic. Pharmacare — preparaty doveria [website]. Accessed Oct 16, 2021. (In Russ.). https://pharmacare.by/publications/dermatology/sovremennye-predstavleniya-o-patogeneze-i-terapii-psoriaza.html
  3. Hairutdinov VR, Belousova IE, Samcov AV. Immune pathogenesis of psoriasis. Vestnik dermatologii I cosmetologii. 2016;4:20-26. (In Russ.). https://doi.org/10.25208/0042-4609-2016-92-4-20-26
  4. Pritulo OA, Richkova IV. Modern ideas about the pathogenesis of psoriasis. Tavricheskii medico-biologicheskii vestnik. 2017;20(1):141-153. (In. Russ.).
  5. Kubanov AA, Bogdanova EV. Epidemiology of psoriasis among the elderly population and volume of specialized medical care provided to patients with psoriasis in the Russian Federation in 2010–2019. Vestnik dermatologii I cosmetologii. 2020;96(5):7-18. (In Russ.). https://doi.org/10.25208/vdv1171-2020-96-5-07-18
  6. Beisebayeva UT, Almenova LT, Khabizhanova AB. Effect of the prevalence of skin process on the dermatological index of the quality of life of psoriasis patients. Vestnik KazNMU. 2018;3:457-459. (In Russ.).
  7. Pashinyan AG, Dvornikov AS, Dontsova EV. The Assessment of Quality of Life in Patients with Psoriasis: a Review of Current Studies. Lechebnoe delo. 2020;2:32-35. (In Russ.). https://doi.org/10.24411/2071-5315-2019-12109
  8. Armstrong AW, Siegel MP, Bagel J. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. Journal of the American Academy of Dermatology. 2017;76(2):290-298.  https://doi.org/10.1016/j.jaad.2016.10.017
  9. Lindqvist T, Salah LA, Gillstedt M, et al. Methotrexate Management in Psoriasis: Are We Following the Guidelines? Acta Derm Venereol. 2018;98:449-451.  https://doi.org/10.2340/00015555-2857
  10. Salihbegovic EV, Hadzigrahic N, Cickusic AJ. Psoriasis and metabolic syndrome. Medical Archives. 2015;69(2):85-87.  https://doi.org/10/5455/medarh.2015/69/85-87
  11. Lykova SG, Nemchaninova OB, Morzhanaeva MA. Psoriasis in patients with metabolic syndrome: clinical aspects of the problem. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2020;19(2):214-222. (In Russ.). https://doi.org/10.17116/klinderma202019021214
  12. Yusupova LA, Latypova AF, Tukhbatullina RG. Somatic pathology in patients with psoriasis. Lechaschy Vrach. 2020;23(11):15-18. (In Russ.). https://doi.org/10.26295/OS.2020.83.29.003
  13. Olisova OYu, Garanyan LG. Comorbidities in psoriasis. Rossiyskii Zhurnal Kozhnykh i Venericheskikh Boleznei. 2016;19(6):346-348. (In Russ.). https://doi.org/10.18821/1560-9588-2016-19-6-346-348
  14. Raaby L, Zachariae C, Østensen V, et al. Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting. Acta Derm Venereol. 2017;97(4):426-432.  https://doi.org/10.2340/00015555-2599
  15. op Vollenbroek FTMB. Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines. PLOS ONE. 2018;13:3.  https://doi.org/10.1371/journal.pone.0194401
  16. Kruglova LS, Ponich ES, Osina AV, et al. Analysis of the various schemes efficiency of methotrexate use in psoriasis treatment. Saratovskii nauchno-medicinskii zhurnal. 2017;13(3):662-668. (In Russ.).
  17. Melnichenko OO. Modern approaches to therapy of grave psoriasis forms. Medicinskii sovet. 2017;11:208-211. (In Russ.). https://doi.org/10.21518/2079-701X-2017-11-208-211
  18. Prokhorov DV, Semkina EV, Vincerskaya GA, Kirilyuk TI, Chopikyan AA. Short-term evaluation of the efficacy and safety of PUVA-therapy in combination with methotrexate in patients with psoriasis. Krimskii medicinskii zhurnal. 2019;3:50-54. (In. Russ.).
  19. Garcíaa DS, Saturansky EI, Poncino D, et al. Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency? Annals of Hepatology. 2019; 18(5):765-769.  https://doi.org/10.1016/j.aohep.2019.01.011
  20. Asoskova AV, Sychev DA, Kubanov AA. Methotrexate safety in psoriasis: an overview. Vestnik RAMN. 2021;76(3):254-267. (In Russ.). https://doi.org/10.15690/vramn1527
  21. Guenther LC, Kunynetz R, Lynde CW, et al. Acitretin use in dermatology. Journal of Cutaneous Medicine and Surgery. 2012;21(35):2-12.  https://doi.org/10.1177/1203475417733414
  22. Neotigason. Instructions for use. (In Russ.).
  23. Valenzuela F, Fernández J, Sánchez M, et al. Erythrodermic psoriasis and human immunodeficiency virus: association and therapeutic challenges. Anais Brasileiros de Dermatologia. 2018;93(3):438-440.  https://doi.org/10.1590/abd1806-4841.20187387
  24. Itoi-Ochi S, Hayashi M, Yamaoka T, et al. Occult HIV infection in Japanese rupioid psoriasis. Letter to the editor. Journal of Dermatology. 2017;44(7):1-2.  https://doi.org/10.1111/1346-8138.13850
  25. Vide J, Magina S. Moderate to severe psoriasis treatment challenges through the era of biological drugs. Anais Brasileiros de Dermatologia. 2017;92(5): 668-674.  https://doi.org/10.1590/abd1806-4841.20175603
  26. Kruglova LS, Hotko AA. Choice of first-line genetically engineered biological drugs for moderate and severe psoriasis in patients with comorbid pathology. Medicinskii alfavin. 2020;24(2):18-22. (In Russ.). https://doi.org/10.33667/2078-5631-2020-24-18-22
  27. Bahlykova EA, Filimonkova NN, Matusevich SL. Comparative assessment of the safety profile of modern drugs used in the treatment of severe forms of psoriasis. Medicinskaya nauka I obrazovanie Urala. 2019;3:10-13. (In Russ.).
  28. Olisova OY, Anpilogova EM. Systemic treatment of psoriasis: from methotrexate to biologics. Vestnik dermatologii i venerologii. 2020;96(3):7-26. (In Russ.). https://doi.org/10.25208/vdv1162
  29. Sabru M-I, Georgescu S-R, Tampa M, et al. Biological therapies in psoriasis. De Gruyter Open. 2018;56(2):75-84.  https://doi.org/10.1515/rjim-2017-0045
  30. Kovtunova VA, Dumchenko VV, Bakhmutova EG, et al. Experience of the long-term use of anticytokine therapy in psoriasis. Rossyiskii zhurnal kozhnyh I venericheskih boleznei. 2017;20(3):163-166. (In Russ.). https://doi.org/10.18821/1560-9588-2017-20-3-163-166
  31. Czarnowicki T, Rosendorff BP, Lebwohl MG. Apremilast and Systemic Retinoid Combination Treatment for Moderate to Severe Palmoplantar Psoriasis. CUTIS. 2020;106(1):15-17.  https://doi.org/10.12788/cutis.0042
  32. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. American Academy of Dermatology. 2020;84(2):432-470.  https://doi.org/10.1016/j.jaad.2020.07.087
  33. Eyerich K, Weisenseel P, Pinter A, et al. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 2021; 11(9):4-13.  https://doi.org/10.1136/bmjopen-2021-049822
  34. Bardazzi F, Magnano M, Campanati A, et al. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience. Acta Dermato-Venereologica. 2017;97(8):989-990.  https://doi.org/10.2340/00015555-2698

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.